220 related articles for article (PubMed ID: 31297947)
1. Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.
Nicolucci A; Charbonnel B; Gomes MB; Khunti K; Kosiborod M; Shestakova MV; Shimomura I; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Tang F; Pocock S
Diabetes Obes Metab; 2019 Nov; 21(11):2474-2485. PubMed ID: 31297947
[TBL] [Abstract][Full Text] [Related]
2. Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme.
Khunti K; Gomes MB; Kosiborod M; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Shimomura I; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Tang F; Ji L;
BMJ Open; 2020 Aug; 10(8):e034613. PubMed ID: 32868349
[TBL] [Abstract][Full Text] [Related]
3. Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study.
Khunti K; Charbonnel B; Cooper A; Gomes MB; Ji L; Leigh P; Nicolucci A; Rathmann W; Shestakova MV; Siddiqui A; Tang F; Watada H; Chen H;
Diabetes Obes Metab; 2021 Aug; 23(8):1823-1833. PubMed ID: 33852202
[TBL] [Abstract][Full Text] [Related]
4. Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries.
Heintjes EM; Overbeek JA; Hall GC; Prieto-Alhambra D; Lapi F; Hammar N; Bezemer ID
Clin Ther; 2017 Nov; 39(11):2296-2310.e14. PubMed ID: 29108837
[TBL] [Abstract][Full Text] [Related]
5. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.
Rathmann W; Bongaerts B; Kostev K
Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
7. Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom.
Abrahami D; D'Andrea E; Yin H; Kim SC; Paik JM; Wexler D; Azoulay L; Patorno E
Diabetes Obes Metab; 2023 Oct; 25(10):2980-2988. PubMed ID: 37395339
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
[TBL] [Abstract][Full Text] [Related]
9. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
[TBL] [Abstract][Full Text] [Related]
10. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink.
Wilding J; Godec T; Khunti K; Pocock S; Fox R; Smeeth L; Clauson P; Fenici P; Hammar N; Medina J
BMC Med; 2018 Jul; 16(1):116. PubMed ID: 30008267
[TBL] [Abstract][Full Text] [Related]
11. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
Montvida O; Shaw JE; Blonde L; Paul SK
Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
[TBL] [Abstract][Full Text] [Related]
12. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance.
Benford M; Milligan G; Pike J; Anderson P; Piercy J; Fermer S
Adv Ther; 2012 Jan; 29(1):26-40. PubMed ID: 22246944
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns in Patients With Newly Diagnosed Type 2 Diabetes in China: A Retrospective, Longitudinal Database Study.
Wang C; Gao Y; Zhu L; Huang M; Wu Y; Xuan J
Clin Ther; 2019 Aug; 41(8):1440-1452. PubMed ID: 31155146
[TBL] [Abstract][Full Text] [Related]
14. Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes.
Gordon J; McEwan P; Evans M; Puelles J; Sinclair A
Diabetes Obes Metab; 2017 May; 19(5):644-653. PubMed ID: 28026911
[TBL] [Abstract][Full Text] [Related]
15. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
16. Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.
Gomes MB; Rathmann W; Charbonnel B; Khunti K; Kosiborod M; Nicolucci A; Pocock SJ; Shestakova MV; Shimomura I; Tang F; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Ji L;
Diabetes Res Clin Pract; 2019 May; 151():20-32. PubMed ID: 30904743
[TBL] [Abstract][Full Text] [Related]
17. Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019.
Heyward J; Christopher J; Sarkar S; Shin JI; Kalyani RR; Alexander GC
Diabetes Obes Metab; 2021 Aug; 23(8):1843-1850. PubMed ID: 33881795
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Klarenbach S; Cameron C; Singh S; Ur E
CMAJ; 2011 Nov; 183(16):E1213-20. PubMed ID: 21969406
[TBL] [Abstract][Full Text] [Related]
19. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
McIntosh B; Cameron C; Singh SR; Yu C; Ahuja T; Welton NJ; Dahl M
Open Med; 2011; 5(1):e35-48. PubMed ID: 22046219
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
